Airsculpt Reports Steep Revenue Decline, Widening Losses, and Material Weakness in Internal Controls for 2025

summarizeSummary

Airsculpt Technologies reported a 15.8% revenue decline, increased net losses, and a material weakness in internal controls for 2025, signaling significant operational and financial challenges.

check_boxKey Events

• Significant Financial Underperformance

  Revenue decreased by 15.8% to $151.8 million in 2025, net loss widened to $(11.7) million, and Adjusted EBITDA declined significantly to $15.1 million. Same-center volume experienced a substantial 22.1% decrease.

• Material Weakness in Internal Controls

  Management concluded that internal control over financial reporting was not effective as of December 31, 2025, due to material weaknesses in general accounting, financial reporting processes, and lease accounting, which required revision of previously issued financial statements.

• Debt Restructuring and Dilutive Equity Offerings

  The company amended its credit agreement in March 2025, modifying financial covenants and increasing interest rates. It raised approximately $13.8 million through an underwritten public offering and $5.6 million via an at-the-market (ATM) program in 2025, with an additional $14.8 million raised via ATM in Q1 2026, to manage liquidity and repay debt.

• London Facility Closure

  Airsculpt closed its London facility in Q4 2025 due to poor financial performance, incurring $2.1 million in net costs related to the closure.

auto_awesomeAnalysis

Airsculpt Technologies' 2025 annual report reveals a company facing significant operational and financial challenges. The substantial decline in revenue, increasing net losses, and a sharp drop in Adjusted EBITDA indicate a deteriorating core business, further exacerbated by a 22.1% decrease in same-center volume. The disclosure of a material weakness in internal control over financial reporting is a critical concern, raising questions about the reliability of financial statements and potentially increasing audit costs and regulatory scrutiny. While the company has taken steps to manage liquidity through debt covenant modifications and dilutive equity offerings, these actions are reactive to financial distress. The closure of the London facility underscores failed international expansion efforts. Investors should be highly cautious, as the combination of operational underperformance and internal control deficiencies presents a challenging outlook.